UBS Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $48
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
UBS analyst Ashwani Verma initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $48.
UBS analyst Ashwani Verma initiates coverage on MapLight Therapeutics (NASDAQ:MPLT) with a Buy rating and announces Price Target of $48.